Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regenxbio

6.29
-0.3800-5.70%
Post-market: 6.290.00000.00%19:49 EDT
Volume:1.09M
Turnover:6.93M
Market Cap:315.04M
PE:-1.37
High:6.55
Open:6.45
Low:6.26
Close:6.67
Loading ...

REGENXBIO Price Target Maintained With a $35.00/Share by RBC Capital

Dow Jones
·
12 Dec 2024

Regenxbio Inc - to Offer and Sell Shares up to $150 Million

THOMSON REUTERS
·
10 Dec 2024

Regenxbio Inc - on Dec 9, Co Enters Sales Agreement With Leerink Partners

THOMSON REUTERS
·
10 Dec 2024

Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

PR Newswire
·
07 Dec 2024

Champion Homes to replace Regenxbio in S&P 600 at open on 12/23

TIPRANKS
·
07 Dec 2024

REGENXBIO Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
21 Nov 2024

Regenxbio Inc. : H.c. Wainwright Cuts Target Price to $36 From $40

THOMSON REUTERS
·
21 Nov 2024

U.S. RESEARCH ROUNDUP- Equifax, Microstrategy, Netflix

Reuters
·
19 Nov 2024

Regenxbio Inc : Leerink Partners Raises Target Price to $38 From $34

THOMSON REUTERS
·
19 Nov 2024

Regenxbio price target raised to $38 from $34 at Leerink

TIPRANKS
·
19 Nov 2024

Sector Update: Health Care Stocks Mixed Premarket Monday

MT Newswires Live
·
18 Nov 2024

Regenxbio Share Surge 20% on Duchenne Muscular Dystrophy Treatment Trial Data, Expansion

Dow Jones
·
18 Nov 2024

Regenxbio Reports Positive Phase I/II Data on RGX-202 Gene Therapy for Duchenne Muscular Dystrophy - Shares Up Pre-Bell

MT Newswires Live
·
18 Nov 2024

BRIEF-Regenxbio Initiates Pivotal Phase Of Affinity Duchenne Trial Of Rgx-202 Gene Therapy

Reuters
·
18 Nov 2024

Regenxbio Initiates Pivotal Phase of Affinity Duchenne® Trial of Rgx-202 Gene Therapy and Reports Positive Functional Data

THOMSON REUTERS
·
18 Nov 2024

Regenxbio Inc - Favorable Safety Profile Observed With No Serious Adverse Events

THOMSON REUTERS
·
18 Nov 2024

Regenxbio Inc - FDA Alignment Achieved for Affinity Duchenne Program, Bla Expected in 2026

THOMSON REUTERS
·
18 Nov 2024

REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA

PR Newswire
·
18 Nov 2024

REGENXBIO Coverage Assumed by Morgan Stanley at Overweight

Dow Jones
·
15 Nov 2024

Regenxbio Inc : Morgan Stanley Assumes Coverage With Overweight Rating; Price Target $22

THOMSON REUTERS
·
15 Nov 2024